Added Sugar Associated with Increased Risk for Death from Cardiovascular Disease
- sugar-sweetened beverages
- grain-based desserts
- fruit drinks
- dairy desserts
- candy.
- A can of regular soda contains about 35g of sugar (about 140 calories).
Quanhe Yang, Ph.D., of the Centers for Disease Control and Prevention, Atlanta, and colleagues used national health survey data to examine added sugar consumption as a percentage of daily calories and to estimate association between consumption and CVD. Study results indicate that the average percentage of daily calories from added sugar increased from 15.7 percent in 1988-1994 to 16.8 percent in 1999 to 2004 and decreased to 14.9 percent in 2005-2010. In 2005-2010, most adults (71.4 percent) consumed 10 percent of more of their calories from added sugar and about 10 percent of adults consumed 25 percent or more of their calories from added sugar. The authors note the risk of death from CVD increased with a higher percentage of calories from added sugar. Regular consumption of sugar-sweetened beverages (seven servings or more per week) was associated with increased risk of dying from CVD. ÛÏOur results support current recommendations to limit the intake of calories from added sugars in U.S. diets,Û the authors conclude. Be warned.
Want the Best Geriatric Care? Go for providers that do a high volume of geriatric patients.
Mediterranean Diet Associated With Lower Risk of Peripheral Artery Disease
Mindfulness Meditation May Help Reduce Anxiety, Depression and Pain
Use of Vitamin E By Patients With Mild to Moderate Alzheimer Disease Slows Functional Decline
Among patients with mild to moderate Alzheimer disease, a daily dosage of 2,000 IUs of vitamin E was effective in slowing functional decline and in reducing caregiver time in assisting patients, according to a study appearing in the January 1 issue of JAMA. Alpha tocopherol, a fat-soluble vitamin (E) and antioxidant, has been studied in patients with moderately severe Alzheimer disease (AD) and in participants with mild cognitive impairment (MCI) but has not been studied in patients with mild to moderate AD. In patients with moderately severe AD, vitamin E was shown to be effective in slowing clinical progression. The drug memantine has been shown to be effective in patients with AD and moderately severe dementia, according to background information in the article. Maurice W. Dysken, M.D., of the Minneapolis VA Health Care System conducted a trial of 613 patients at 14 Veterans Affairs medical centers. Participants received either 2,000 IU/day of vitamin E (n = 152), 20 mg/d of memantine (n = 155), the combination (n = 154), or placebo (n = 152). Change in functional decline was gauged via the Alzheimer’s Disease Cooperative Study/Activities of Daily Living (ADCS-ADL) Inventory score (range, 0-78). Over the average follow-up time of 2.3 years, participants receiving vitamin E had slower functional decline than those receiving placebo, with the annual rate of decline in ADLs reduced by 19 percent. This treatment effect translates into a clinically meaningful delay in progression in the vitamin E group of 6.2 months. Neither memantine nor the combination of vitamin E and memantine showed clinical benefit in this trial. In addition, caregiver time was reduced by about 2 hours per day in the vitamin E group. The authors write that the current study is one of the largest and longest treatment trials in patients with mild to moderate AD. The researchers note that decline in functioning in AD is increasingly recognized as an important determinant of both patient quality of life and social and economic costs. Check with your physician.